8-K: Ardelyx Reports Strong Q3 2024 Results Driven by IBSRELA and XPHOZAH Sales

Ardelyx announced strong third-quarter 2024 financial results, highlighted by significant revenue growth from both IBSRELA and XPHOZAH, and updated its full-year sales guidance for IBSRELA.

Summary

• Ardelyx reported its financial results for the third quarter of 2024, showing substantial growth in revenue.
• IBSRELA generated $40.6 million in net product sales, a 15% increase compared to the previous quarter and a significant increase from $22.3 million in the same quarter of 2023.
• XPHOZAH recorded $51.5 million in net product sales, a 39% increase compared to the second quarter of 2024.
• Total revenue for the quarter was $98.2 million, compared to $56.4 million in the same period last year.
• The company ended the quarter with approximately $190 million in cash, cash equivalents, and investments.
• Ardelyx has revised its full-year 2024 net sales revenue guidance for IBSRELA to be between $145 and $150 million.
• The company amended its loan agreement with SLR Capital Partners, drawing $50 million and securing an option for an additional $50 million, extending the interest-only period to July 1, 2028.
• The net loss for the quarter was $0.8 million, compared to a net income of $6.6 million in the same quarter of 2023, which included share-based compensation expense of $9.1 million and non-cash interest expense of $1.9 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth and a solid cash position, although there is a net loss for the quarter and increased expenses. The company has also secured additional funding.

Positives

• Both IBSRELA and XPHOZAH demonstrated strong sales growth, indicating successful commercialization.
• IBSRELA sales increased by 15% quarter-over-quarter, showing consistent growth.
• XPHOZAH sales increased by 39% quarter-over-quarter, highlighting strong market demand.
• The company has a strong cash position of approximately $190 million.
• The amended loan agreement provides additional financial flexibility with an extended interest-only period.
• The company has increased its full year sales guidance for IBSRELA.

Negatives

• The company reported a net loss of $0.8 million for the quarter, compared to a net income of $6.6 million in the same quarter of 2023.
• Selling, general, and administrative expenses increased significantly to $65.0 million, primarily due to commercialization efforts.
• Licensing revenue decreased significantly from $32 million to $20 thousand due to the timing of milestone payments.

Risks

• The company faces risks associated with the commercialization of drugs in the U.S. and internationally.
• There is a planned change in Medicare Part D reimbursement for XPHOZAH in early January 2025, which could impact patient access.
• The company's future performance is subject to uncertainties related to regulatory processes and market adoption of its products.
• The company has a warning about the risk of serious dehydration in pediatric patients using IBSRELA.

Future Outlook

Ardelyx anticipates continued growth for IBSRELA and XPHOZAH and is focused on expanding its business while ensuring patient access to its medications. The company expects full-year 2024 IBSRELA net sales to be between $145 and $150 million.

Management Comments

• The continued strong performance of Ardelyx reported during the third quarter demonstrates our ability to execute and deliver on our goals, to focus on serving the patient and to build towards the future, said Mike Raab, president and chief executive officer of Ardelyx.
• We remain committed to ensuring that this well-tolerated, effective and differentiated medicine remains available to patients, despite CMS planned change in Medicare Part D reimbursement in early-January 2025, and we are confident that we have made decisions that will best support our efforts to protect patient access to XPHOZAH.

Industry Context

The results reflect a growing demand for treatments for IBS-C and hyperphosphatemia, aligning with the broader trend of increased focus on gastrointestinal and kidney-related therapies. The company's performance indicates a strong position in these markets.

Comparison to Industry Standards

• Ardelyx's 15% quarter-over-quarter growth for IBSRELA is strong compared to other IBS-C treatments, which often see slower adoption rates.
• The 39% quarter-over-quarter growth for XPHOZAH is impressive, indicating a significant unmet need in the hyperphosphatemia market, and is likely higher than many competitors in the same space.
• Companies like Ironwood Pharmaceuticals (IRWD) and Synergy Pharmaceuticals (now defunct) have previously marketed IBS-C treatments, but Ardelyx's growth rate appears to be outpacing historical trends.
• In the hyperphosphatemia space, competitors like Akebia Therapeutics (AKBA) and Keryx Biopharmaceuticals (now part of Vifor Pharma) have faced challenges in market penetration, making Ardelyx's launch of XPHOZAH particularly noteworthy.
• The company's ability to secure additional debt financing and extend the interest-only period is a positive sign compared to other biotech companies that may struggle with funding.

Management Changes

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and positive sales guidance favorably.
• Employees may benefit from the company's growth and expansion.
• Patients will have continued access to IBSRELA and XPHOZAH.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial position as stable.

Next Steps

• The company will continue to focus on the commercialization of IBSRELA and XPHOZAH.
• Ardelyx will monitor the impact of the planned Medicare Part D reimbursement change for XPHOZAH.
• The company will continue to invest in expanding its business.

Key Dates

Keywords

IBSRELA, XPHOZAH, tenapanor, net product sales, revenue, hyperphosphatemia, IBS-C, financial results, biopharmaceutical, commercialization